Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

16.7%

1 terminated out of 6 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

6Total
P 1 (2)
P 2 (3)
P 3 (1)

Trial Status

Unknown3
Withdrawn1
Active Not Recruiting1
Terminated1

Clinical Trials (6)

Showing 6 of 6 trials
NCT04159155Phase 2Terminated

A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

NCT03611868Phase 1Active Not Recruiting

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

NCT03377725Phase 3Withdrawn

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

NCT03855371Phase 1UnknownPrimary

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

NCT04906031Phase 2Unknown

Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations

NCT03381781Phase 2Unknown

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Showing all 6 trials

Research Network

Activity Timeline